Podcasts about axitinib

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with Prof. Roberto Iacovelli (IT), Gostino Gemelli University Polyclinic, Rome, about the abstract he presented at ESMO 2023, "The TIDE-A study: Phase II study of avelumab (Ave) plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma".  Prof. Iacovelli shares details on the TIDE-A study, the first study demonstrating the potential benefits of VEGFR-TKI interruption combined with immunotherapy. Results showed decreased treatment-related toxicity and delayed tumour progression in mRCC patients. The safety of the combination of avelumab and axitinib in mRCC patients was also promising, and he suggests that future investigations in a randomised trial would be worthwhile.

Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng

Drs Sumanta Pal and Jose A. Karam, MD, discuss neoadjuvant therapy in renal cell carcinoma, including TKIs, immuno-oncology, and the need for more studies to explore the role of neoadjuvant therapy in RCC. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984249). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Renal Cell Carcinoma https://emedicine.medscape.com/article/281340-overview Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges Into Opportunities https://pubmed.ncbi.nlm.nih.gov/35248412/ Axitinib https://reference.medscape.com/drug/inlyta-axitinib-999715#10 Phase 2 Trial of Neoadjuvant Axitinib in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/24560330/ Renal Clear Cell Cancer https://www.ncbi.nlm.nih.gov/books/NBK563230/ Response Evaluation Criteria in Solid Tumors https://radiopaedia.org/articles/response-evaluation-criteria-in-solid-tumours?lang=us Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/ Tyrosine Kinase Inhibitors and Immunotherapy Combinations in Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/32215057/ A Phase II Study of Pazopanib in Patients With Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma https://pubmed.ncbi.nlm.nih.gov/25813447/ Bevacizumab (Rx) https://reference.medscape.com/drug/avastin-mvasi-bevacizumab-342257 Everolimus (Rx) https://reference.medscape.com/drug/afinitor-zortress-everolimus-999101 Nivolumab (Rx) https://reference.medscape.com/drug/opdivo-nivolumab-999989 A Pilot Randomized Study Evaluating Nivolumab (Nivo) Or Nivo + Bevacizumab (Bev) Or Nivo + Ipilimumab (Ipi) in Patients With Metastatic Renal Cell Carcinoma (MRCC) Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy (Bx) https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4501 Ipilimumab (Rx) https://reference.medscape.com/drug/yervoy-ipilimumab-999636#10 TNM Classification https://www.ncbi.nlm.nih.gov/books/NBK553187/ A Phase II, Single-Arm Trial of Neoadjuvant Axitinib Plus Avelumab in Patients With Localized Renal Cell Carcinoma Who Are at High Risk of Relapse After Nephrectomy (NEOAVAX) https://pubmed.ncbi.nlm.nih.gov/31023100/ Inferior Venal Caval Thrombus https://emedicine.medscape.com/article/1933035-overview A Phase II Study of Neoadjuvant Axitinib for Reducing the Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion (NAXIVA) https://pubmed.ncbi.nlm.nih.gov/35739300/ Surgical Management of Renal Cell Carcinoma With Associated Tumor Thrombus Extending Into the Inferior Vena Cava: A 10-Year Single-Center Experience https://pubmed.ncbi.nlm.nih.gov/30817278/

This podcast covers topics including the metastatic renal cell carcinoma landscape with a focus on immune-oncology (IO) agents and tyrosine kinase inhibitors, axitinib indication (combination and monotherapy), a summary of efficacy and safety data, dose modification guidelines, and author experience of managing patients with the most common adverse events (AEs) encompassing prior to initiating therapy, patient education, and follow-up.   This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapywebsite and by using this link: https://link.springer.com/article/10.1007/s12325-023-02513-1. All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Pr Pierre Bigot : Highlights des recommandations CCAFU 2020-2022 du cancer du reinQuelles sont les messages clés des nouvelles recommandations ? Quelles sont les nouveautés dans la prise en charge chirurgicale du cancer du rein métastatique ? Quelles sont les nouveautés dans le traitement médical de première ligne du cancer du rein métastatique ? Quels messages retenir pour les tumeurs kystiques et les angiomyolipomes sporadiques ?Le Pr Pierre Bigot (CHU d’Angers) répond à toutes vos questions !L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode.Cet épisode a été réalise grâce au soutien institutionnel des laboratoires IPSENPour aller plus loin :Recommandations françaises du Comité de Cancérologie de l’AFU : actualisation 2020-2022 : prise en charge du cancer du reinhttps://purol-12s.elsevierdigitaledition.com/2/https://www.urofrance.org/outils-et-recommandations/recommandations/recommandations-afu/classees-par-annee.htmlÉtude Carmena :Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3. PMID: 29860937.Etude SURTIME :Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271. PMID: 30543350; PMCID: PMC6439568.Keynote 426 :Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. PMID: 30779529. Checkmate 214 :Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PMID: 29562145; PMCID: PMC5972549. Cet épisode a été réalisé grâce au soutien institutionnel des laboratoires IPSEN.Musique du générique : Via AudioNetworkResponsable projet

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:Treating beyond progression with immunotherapyManagement of patients with less common histologic subtypes of RCCPotential biomarkers for RCCAdverse event managementPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:•           Treatment sequencing with IO and TKI therapies•           Optimizing dose for patients with preexisting toxicities•           Considerations for local control of metastatic sites •           Ongoing clinical trials Presenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:Choice of first-line therapyCombinations of targeted agents and immunotherapyCombinations of immune checkpoint inhibitorsActive surveillance and monitoringCytoreductive nephrectomyPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.Link to full program: https://bit.ly/32IS9gx

Quel traitement de première ligne proposer pour un cancer du rein métastatique ?Quelle classification pronostique utiliser ? Faut-il encore faire une néphrectomie de cytoréduction ?Quelles sont les dernières actualités dans le cancer du rein métastatique ?Le Pr Arnaud Mejean (Hôpital Européen Georges Pompidou) répond à toutes vos questions !L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode.Pour aller plus loin :- Lire ici : Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2 août 2018;379(5):417‑27.- Lire ici : Bex A, Mulders P, Jewett M, Wagstaff J, Thienen JV van, Blank CU, et al. Comparisonof Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 1 févr 2019;5(2):164‑70.- Lire ici : Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 21 mars 2019;380(12):1116‑27.- Lire ici : Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 21 mars 2019;380(12):1103‑15.- Lire ici : otzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 5 avr 2018;378(14):1277‑90.- Lire ici : Recommandations françaises du comité de cancérologie de l’AFU – Actualisation 2020 : Prise en charge du cancer du rein métastatique.Réalisé avec le soutien institutionnel des laboratoires Ipsen.Musique du générique : Via AudioNetworkResponsable projet AFUF : Dr Benjamin PradèreProduction : La Toile Sur Ecoute See acast.com/privacy for privacy and opt-out information.

Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds.

Axitinib studies presented at ASCO-GU '19 with simultaneous NEJM publication are discussed, followed by a brief overview (18:50) of darolutamide, a new anti-androgen, and its drug interaction potential.

Dr Voss talks to ecancertv at ASCO GU 2015 on part 1 of the DART Study, a phase II randomised trial using dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma. Results have shown that the combination of dalantercept and axitinib is well tolerated and demonstrated and associated with encouraging activity in patients with prior VEGF, mTOR, and immune therapies.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Commentary on a new small molecule inhibitor of angiogenesis in combination with chemotherapy for metastatic breast cancer.